#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	531	15342	16S	1529	1529	99.93	16S.l15.c4.ctg.1	2056	740.5	0	.	n	.	0	C1450T	SNP	1450	1450	C	1684	1684	T	863	T	790	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	531	15342	16S	1529	1529	99.93	16S.l15.c4.ctg.1	2056	740.5	1	SNP	n	C1184T	0	.	.	1184	1184	C	1418	1418	C	850	C	795	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	27982	23S	2890	2890	99.93	23S.l15.c17.ctg.1	3435	810.9	0	.	n	.	0	G1337A	SNP	1337	1337	G	1663	1663	A	949	A	881	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	27982	23S	2890	2890	99.93	23S.l15.c17.ctg.1	3435	810.9	0	.	n	.	0	T1971C	SNP	1971	1971	T	2297	2297	C	917	C,T	838,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	27982	23S	2890	2890	99.93	23S.l15.c17.ctg.1	3435	810.9	1	SNP	n	A2045G	0	.	.	2045	2045	A	2371	2371	A	894	A	845	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	27982	23S	2890	2890	99.93	23S.l15.c17.ctg.1	3435	810.9	1	SNP	n	C2597T	0	.	.	2597	2597	C	2923	2923	C	876	C	825	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
blaTEM.WHO_M_pConjugative_00003	blaTEM.WHO_M_pConjugative_00003	1	0	1	32	blaTEM	861	402	100.0	blaTEM.l15.c30.ctg.1	559	3.2	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	Betalactam resistance
blaTEM.WHO_M_pConjugative_00003	blaTEM.WHO_M_pConjugative_00003	1	0	1	32	blaTEM	861	368	100.0	blaTEM.l15.c30.ctg.2	378	2.4	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	Betalactam resistance
folP.WHO_Y_01480c	folP.WHO_Y_01480c	1	1	27	2100	folP	855	855	100.0	folP.l15.c4.ctg.1	1488	140.9	1	SNP	p	R229S	1	.	.	685	687	AGC	1008	1010	AGC	196;193;191	A;G;C	183;179;178	folP.WHO_Y_01480c:1:1:R229S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	5494	gyrA	2751	2751	99.96	gyrA.l15.c4.ctg.1	3321	165.0	1	SNP	p	S91F	1	.	.	271	273	TTC	546	548	TTC	203;205;206	T;T;C	192;193;192	gyrA.WHO_M_01098:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	5494	gyrA	2751	2751	99.96	gyrA.l15.c4.ctg.1	3321	165.0	1	SNP	p	D95G	1	.	.	283	285	GGC	558	560	GGC	213;213;214	G;G;C	196;193;192	gyrA.WHO_M_01098:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	5494	gyrA	2751	2751	99.96	gyrA.l15.c4.ctg.1	3321	165.0	1	SNP	p	G95N	0	.	.	283	285	GGC	558	560	GGC	213;213;214	G;G;C	196;193;192	gyrA.WHO_M_01098:1:1:G95N:gyrA.95N:Resistance to fluoroquinolones	.
mtrR.WHO_V_01454	mtrR.WHO_V_01454	1	1	27	1742	mtrR	633	633	100.0	mtrR.l15.c30.ctg.1	1363	127.4	1	SNP	p	G45D	0	.	.	133	135	GGC	503	505	GGC	213;214;218	G;G;C	191;191;199	mtrR.WHO_V_01454:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	531	886	mtrR_promoter	250	250	99.6	mtrR_promoter.l15.c30.ctg.1	1001	87.8	0	.	n	.	0	A197.	DEL	197	197	A	493	493	A	220	A	201	.	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	5134	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3041	168.3	1	SNP	p	D86N	0	.	.	256	258	GAC	659	661	GAC	202;202;206	G;A;C	193;190;195	parC.WHO_Y_00247c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	5134	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3041	168.3	1	SNP	p	R87W	0	.	.	259	261	CGT	662	664	CGT	207;209;208	C;G;T	198;196;195	parC.WHO_Y_00247c:1:1:R87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	5134	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3041	168.3	1	SNP	p	S87R	1	.	.	259	261	CGT	662	664	CGT	207;209;208	C;G;T	198;196;195	parC.WHO_Y_00247c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	5134	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3041	168.3	1	SNP	p	R87I	0	.	.	259	261	CGT	662	664	CGT	207;209;208	C;G;T	198;196;195	parC.WHO_Y_00247c:1:1:R87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	5134	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3041	168.3	1	SNP	p	S88P	0	.	.	262	264	TCC	665	667	TCC	208;212;213	T;C,T;C	197;199,1;201	parC.WHO_Y_00247c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	539	4556	parE	1986	1986	99.95	parE.l15.c4.ctg.1	2728	166.5	0	.	p	.	0	R340C	NONSYN	1018	1020	CGC	1398	1400	TGC	207;206;206	T;G;C	187;189;191	.	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	539	4556	parE	1986	1986	99.95	parE.l15.c4.ctg.1	2728	166.5	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1608	1610	GGC	229;231;227	G;G,A;C	217;219,1;212	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.12.001	penA.12.001	1	1	27	4328	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2286	188.5	1	SNP	p	A311V	0	.	.	931	933	GCA	1207	1209	GCA	251;250;252	G;C;A	219;215;217	penA.12.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	4328	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2286	188.5	1	SNP	p	I312M	0	.	.	934	936	ATC	1210	1212	ATC	254;254;255	A;T;C	222;221;221	penA.12.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	4328	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2286	188.5	1	SNP	p	V316T	0	.	.	946	948	GTG	1222	1224	GTG	267;268;266	G,A;T;G	232,1;234;231	penA.12.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	4328	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2286	188.5	1	SNP	p	V316P	0	.	.	946	948	GTG	1222	1224	GTG	267;268;266	G,A;T;G	232,1;234;231	penA.12.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	4328	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2286	188.5	1	SNP	p	T484S	0	.	.	1450	1452	ACC	1726	1728	ACC	227;224;226	A;C;C	206;207;210	penA.12.001:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	4328	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2286	188.5	1	SNP	p	A502V	0	.	.	1504	1506	GCG	1780	1782	GCG	208;208;210	G,A;C,G;G,A	183,1;168,1;174,1	penA.12.001:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	4328	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2286	188.5	1	SNP	p	A502P	0	.	.	1504	1506	GCG	1780	1782	GCG	208;208;210	G,A;C,G;G,A	183,1;168,1;174,1	penA.12.001:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	4328	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2286	188.5	1	SNP	p	G543S	0	.	.	1627	1629	GGC	1903	1905	GGC	207;210;210	G;G;C	185;187;188	penA.12.001:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	4328	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2286	188.5	1	SNP	p	G546S	0	.	.	1636	1638	GGC	1912	1914	GGC	215;217;219	G,C;G;C	189,1;193;195	penA.12.001:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	4328	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2286	188.5	1	SNP	p	P552S	1	.	.	1654	1656	TCG	1930	1932	TCG	216;217;222	T,G;C;GCCC,GCCCC	148,11;167;176,1	penA.12.001:1:1:P552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	6124	ponA	2397	2397	100.0	ponA.l15.c4.ctg.1	3064	199.2	1	SNP	p	L421P	1	.	.	1261	1263	CCG	1599	1601	CCG	202;201;203	C;C;G	185;188;187	ponA.WHO_G_00106:1:1:L421P:ponA.421P:High-level chromosomally-mediated penicillin resistance	.
porA.NCCP11945	porA.NCCP11945	1	0	531	2552	porA	1146	1146	99.56	porA.l15.c17.ctg.1	1730	146.3	0	.	p	.	0	M83fs	FSHIFT	247	247	A	610	610	C	174	C	160	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2826	porB1b	1047	1047	99.14	porB1b.l15.c4.ctg.1	1459	191.9	0	.	p	.	0	N38E	NONSYN	112	114	AAT	402	404	GAA	244;247;248	G;A;A	226;231;232	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2826	porB1b	1047	1047	99.14	porB1b.l15.c4.ctg.1	1459	191.9	0	.	p	.	0	N134D	NONSYN	400	402	AAT	690	692	GAT	233;234;235	G;A;T	216;214;214	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2826	porB1b	1047	1047	99.14	porB1b.l15.c4.ctg.1	1459	191.9	0	.	p	.	0	P175S	NONSYN	523	525	CCA	813	815	TCA	241;243;244	T;C;A	221;223;226	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2826	porB1b	1047	1047	99.14	porB1b.l15.c4.ctg.1	1459	191.9	0	.	p	.	0	A218V	NONSYN	652	654	GCC	942	944	GTC	273;277;273	G,A;T;C,G	245,1;249;243,1	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2826	porB1b	1047	1047	99.14	porB1b.l15.c4.ctg.1	1459	191.9	0	.	p	.	0	F222L	NONSYN	664	666	TTT	954	956	CTT	265;263;264	C,T;T;T	236,1;239;239	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2826	porB1b	1047	1047	99.14	porB1b.l15.c4.ctg.1	1459	191.9	0	.	p	.	0	E328A	NONSYN	982	984	GAA	1272	1274	GCA	175;174;173	G;C;A	165;164;161	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2826	porB1b	1047	1047	99.14	porB1b.l15.c4.ctg.1	1459	191.9	0	.	p	.	0	D333V	NONSYN	997	999	GAC	1287	1289	GTC	170;170;168	G;T;C,A	153;152;153,1	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2826	porB1b	1047	1047	99.14	porB1b.l15.c4.ctg.1	1459	191.9	1	SNP	p	G120K	1	.	.	358	360	AAG	648	650	AAG	224;223;224	A;A;G	205;206;208	porB1b.WHO_V_02265c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2826	porB1b	1047	1047	99.14	porB1b.l15.c4.ctg.1	1459	191.9	1	SNP	p	D121N	0	.	.	361	363	GAC	651	653	GAC	224;225;226	G;A;C	205;207;207	porB1b.WHO_V_02265c:1:1:D121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2826	porB1b	1047	1047	99.14	porB1b.l15.c4.ctg.1	1459	191.9	1	SNP	p	A121D	1	.	.	361	363	GAC	651	653	GAC	224;225;226	G;A;C	205;207;207	porB1b.WHO_V_02265c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_M_02157	rpoB.WHO_M_02157	1	1	27	10770	rpoB	4179	4179	100.0	rpoB.l15.c4.ctg.1	4822	222.9	1	SNP	p	H553N	1	.	.	1657	1659	AAT	2009	2011	AAT	212;214;214	A,C;A;T	201,1;200;201	rpoB.WHO_M_02157:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	1170	rpsJ	312	312	100.0	rpsJ.l15.c30.ctg.1	985	117.9	1	SNP	p	V57M	1	.	.	169	171	ATG	491	493	ATG	253;254;251	A;T;G	233;232;233	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
